Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study

Abstract: Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospec...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S. Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M. Ross
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-03-01
Schriftenreihe:	Blood Advances
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S247395292400750X
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!